SCHEMBL2813369

SCHEMBL2813369

CSC(=CSc1ccccc1)C(=O)Nc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.46
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
MAPT P10636 4/20 0.46
HSD17B10 Q99714 2/20 0.46
POLB P06746 2/20 0.46
MAPK1 P28482 2/20 0.46
TP53 P04637 2/20 0.46
RAB9A P51151 7/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
NAPRT Q6XQN6 1/20 0.43
NPC1 O15118 6/20 0.42
NFKB1 P19838 2/20 0.42
NFKB2 Q00653 2/20 0.42
RELA Q04206 2/20 0.42
KDM4E B2RXH2 2/20 0.42
PKM P14618 2/20 0.42
ALDH1A1 P00352 2/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2813368 1.00 SMN1; SMN2 (0.46) SMN1; SMN2MEN1KMT2AMAPTHSD17B10
SCHEMBL2808535 0.90 RAB9A (0.45) SMN1; SMN2MEN1KMT2AMAPTPOLB
SCHEMBL2808537 0.90 RAB9A (0.45) SMN1; SMN2MEN1KMT2AMAPTPOLB
SCHEMBL2811449 0.87 SMN1; SMN2 (0.43) SMN1; SMN2MEN1KMT2AMAPTHSD17B10
SCHEMBL2811451 0.87 SMN1; SMN2 (0.43) SMN1; SMN2MEN1KMT2AMAPTHSD17B10
SCHEMBL12851365 0.87 SMN1; SMN2 (0.43) SMN1; SMN2MEN1KMT2AMAPTHSD17B10
SCHEMBL2812831 0.82 HSD17B10 (0.53) SMN1; SMN2MEN1KMT2AMAPTHSD17B10
SCHEMBL2812834 0.82 HSD17B10 (0.53) SMN1; SMN2MEN1KMT2AMAPTHSD17B10
SCHEMBL2812612 0.81 MAPT (0.42) SMN1; SMN2MEN1KMT2AMAPTHSD17B10
SCHEMBL2812614 0.81 MAPT (0.42) SMN1; SMN2MEN1KMT2AMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318981-B2 Imidate compound and use thereof for pest control SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-11-27 US disclosed
US-8278473-B2 Alpha, beta-unsaturated imidate compound and pesticidal composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-02 US disclosed
US-20100240729-A1 ALPHA, BETA-UNSATURATED IMIDATE COMPOUND AND PESTICIDAL COMPOSITION CONTAINING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-09-23 US disclosed
US-20100210683-A1 IMIDATE COMPOUND AND USE THEREOF FOR PEST CONTROL SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2010-08-19 US disclosed
EP-2183215-A2 IMIDATE COMPOUND AND USE THEREOF FOR PEST CONTROL Sumitomo Chemical Company, Limited (JP) 2010-05-12 EP disclosed
WO-2009064031-A1 ALPHA, BETA-UNSATURATED IMIDATE COMPOUND AND PESTICIDAL COMPOSITION CONTAINING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-05-22 WO disclosed
WO-2009064031-A1 ALPHA, BETA-UNSATURATED IMIDATE COMPOUND AND PESTICIDAL COMPOSITION CONTAINING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-05-22 WO disclosed
WO-2009014267-A2 IMIDATE COMPOUND AND USE THEREOF FOR PEST CONTROL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240729-A1 ALPHA, BETA-UNSATURATED IMIDATE COMPOUND AND PESTICIDAL COMPOSITION CONTAINING THE SAME OXER1, CBR1, DEGS1 SMN1; SMN2 1135/4885MEN1 3112/4885KMT2A 3324/4885
US-20100210683-A1 IMIDATE COMPOUND AND USE THEREOF FOR PEST CONTROL CYP1A1, CYC1, C1S SMN1; SMN2 1829/4885MEN1 1642/4885KMT2A 1055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.